Lombard Odier Asset Management USA Corp Invests $307,000 in Twist Bioscience Co. (NASDAQ:TWST)

Lombard Odier Asset Management USA Corp acquired a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,221 shares of the company’s stock, valued at approximately $307,000.

Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its stake in Twist Bioscience by 34.8% in the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares during the last quarter. UBS Group AG lifted its holdings in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after purchasing an additional 110,036 shares during the last quarter. SageView Advisory Group LLC bought a new stake in Twist Bioscience in the first quarter worth $1,144,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Twist Bioscience in the first quarter worth approximately $300,000. Finally, Sei Investments Co. raised its holdings in shares of Twist Bioscience by 32.7% during the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after purchasing an additional 55,124 shares during the last quarter.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,114 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total value of $53,472.00. Following the transaction, the chief executive officer now directly owns 504,732 shares in the company, valued at $24,227,136. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total value of $53,472.00. Following the completion of the sale, the chief executive officer now directly owns 504,732 shares of the company’s stock, valued at $24,227,136. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dennis Cho sold 709 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the transaction, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,125 shares of company stock valued at $664,784. Corporate insiders own 3.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. TD Cowen upped their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. The Goldman Sachs Group raised their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Finally, Guggenheim assumed coverage on Twist Bioscience in a research note on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price on the stock. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Twist Bioscience Price Performance

TWST opened at $45.29 on Tuesday. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The business has a fifty day moving average price of $47.05 and a 200 day moving average price of $43.14. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -13.48 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period last year, the company earned ($1.01) EPS. The business’s quarterly revenue was up 27.7% compared to the same quarter last year. On average, research analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.